Sunesis, UCSF in research agreement to identify small molecule drug candidates

By Lisa Kerner

Erie, Pa., April 7 - Sunesis Pharmaceuticals, Inc. said it has entered into a research and license agreement with the University of California, San Francisco (UCSF), granting the university a limited license to use Sunesis' fragment-based drug discovery technology, Tethering, for academic purposes.

The university intends to leverage Sunesis' technology to identify novel small molecule drug candidates, according to a company news release.

Under the agreement, Sunesis receives an exclusive royalty-free license to any improvements to its technology or fragment libraries that emerge from the university's research, as well as first rights to any small molecules discovered using the Tethering technology.

The agreement also restricts the university from using the technology for commercial purposes and from conducting research in the kinase field or on any other drug target on which Sunesis is working, the release stated.

Sunesis is a clinical-stage biopharmaceutical company that discovers, develops and commercializes novel small molecule therapeutics for oncology and other diseases. The company is located in South San Francisco.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.